Tag: Heart / Stroke-Related: High Cholesterol
Favorable Trends Seen in Lipids, Apolipoprotein B in U.S. Youth
Adjusted mean total cholesterol level decreased from 1999-2000 to 2015-2016 in youth aged 6 to 19 years
One-Third of Patients on Statins Do Not Reach Target Thresholds
Not reaching thresholds places patients at increased risk for cardiovascular events
Longer Duration of Statin Use Linked to Lower Risk for Glaucoma
Self-reported high cholesterol levels without statin use tied to higher glaucoma risk
Machine Learning IDs Risk for Familial Hypercholesterolemia
Classifier developed using EHR data identifies patients at highest probability threshold for FH
Adding Bempedoic Acid to Statin Therapy Reduces LDL Cholesterol
Genetic variants mimicking effect of ATP citrate lyase inhibitors, statins lower LDL-C in same way
Achievement of Targets in T2DM Varies by Season
Achievement rates for all three targets and for HbA1c, BP, LDL-C are lowest in the winter
Lowering BP, Lipids in Healthy Elderly Has No Cognitive Effect
Candesartan/hydrochlorothiazide, rosuvastatin, combination therapy do not affect cognitive decline
Higher Triglycerides May Be Protective in the Very Elderly
Higher triglyceride levels tied to lower risk of cognitive decline, ADL decline, frailty aggravation, and death
Price of Alirocumab Would Have to Be Cut to Be Cost-Effective
Price of alirocumab would have to decrease from original cost of $14,560 to $1,974 to be cost-effective
Adherence and Intensity of Lipid-Lowering Tx Influence CV Risk
Lowest risk seen for adherent patients receiving high-intensity statin and/or ezetimibe regimen
